About IQB@R

Our Vision and Mission

Vision

Rutgers system-wide center-of-excellence for interdisciplinary quantitative biomedical research.

Mission

  1. To foster a vibrant, cohesive community of Rutgers basic, applied, and clinical scientists committed to collaborative application of tools from biology, chemistry, computer science, engineering, linguistics, materials science, mathematics, physics, and statistics to grand challenges in biomedical research.
  2. To develop next generation researchers expert in the quantitative sciences for careers working at the interface with biology and medicine.

Formation

The Institute for Quantitative Biomedicine at Rutgers was established in the wake of the historic merger of Rutgers, The State University of New Jersey, with the University of Medicine and Dentistry of New Jersey (UMDNJ) as part of the university-wide strategic planning process initiated by President Robert L. Barchi. A competitive proposal to establish IQB@R, submitted in response to a call from the Office of the New Brunswick Chancellor, Dr. Richard L. Edwards, was formally approved by the University Board of Governors in December 2014.

The Institute was officially launched on July 1st 2015 to engage scientists from across the entire Rutgers system and foster creation of the biomedical research university of the future. This new initiative occurs in the midst of an unprecedented period of growth in access to patient genome sequences and complementary data coming from high-throughput measurements of biological systems. 

The “perfect storm” of institutional change at Rutgers and the Data Science revolution provided the opportunity to establish a broadly inclusive center-of-excellence dedicated to collaborative application of tools from the quantitative sciences to grand challenges in biology and medicine. 

Rutgers educators, researchers, and clinicians participating in various Institute activities are working together to redefine how the quantitative sciences of a traditionally structured research university will interoperate with the basic science and clinical departments of two major medical schools.

Leadership

IQB@R was founded by Distinguished Professor of Chemistry and Chemical Biology Stephen K. Burley, M.D., D.Phil., who also serves as Director of the Center for Integrative Proteomics Research and the RCSB Protein Data Bank and as a Member of the Rutgers Cancer Institute of New Jersey. Dr. Gail Ferstandig Arnold serves as the Associate Director of the Institute. Dr. Ferstandig Arnold also holds the rank of Research Professor, and previously served in a scientific leadership role in the Rutgers Center for Advanced Biotechnology and Medicine.

Membership

IQB@R Members will be drawn from the Schools of Arts and Sciences (SAS), Engineering (SOE), Environmental and Biological Sciences (SEBS), and Pharmacy (SOP), the Rutgers Cancer Institute of New Jersey (CINJ), the Center for Advanced Biotechnology and Medicine (CABM), the Child Health Institute of New Jersey (CHINJ), the Environmental and Occupational and Health Sciences Institute (EOHSI), the Human Genetics Institute of New Jersey (HGINJ/RUCDR Infinite Biologics), the New Jersey Institute for Food, Nutrition, and Health (NJIFNH), the New Jersey Medical School (NJMS), the Robert Wood Johnson Medical School (RWJMS), the Waksman Institute of Microbiology (WIM), and the Office of Research and Economic Development (ORED). 

Administrative Offices

The administrative offices of the Institute are housed within the Center for Integrative Proteomics Research (Proteomics, Rooms 105 and 106).

Initial Priorities

During Year One of Institute operations efforts will be focused on the following tasks:

  1. Forming two interdisciplinary Research Working Groups in Cancer Genomics and Proteomics (Co-Chairs: Ganesan and Burley) and  AntiMicrobial Resistance (Co-Chairs: Perlin and Burley). Initial focus on these two research areas  will build on considerable strengths resulting from the Rutgers/University of Medicine and Dentistry New Jersey merger. Both teams will develop short- and medium-term research plans,  informed by deep subject matter expertise and the outcomes of SWOT (Strengths, Weaknesses,  Opportunities, and Threats) analyses. Both inaugural Working Groups will be expected to seek federal funds to support collaborative research coming from these deliberations. During the latter  part of Year One, the Institute will identify additional Research Working Groups that will be  formed during Years Two and Three.
  2. Establishing the Rutgers New Jersey Core Facility for Cryo-Electron Microscopy and Tomography that will be housed in a custom design/build microscopy suite located on the Ground Floor of  Proteomics. The facility will be equipped with a 200 keV Scanning Transmission Electron  Microscope equipped with state-of-the-art direct electron detection. This instrument will be the first of its kind in New Jersey, enabling high-resolution structural studies of large macromolecular  complexes of importance in human health and disease. The facility will be operated by an expert  technical staff and will be made available on a tiered fee-for-service basis to scientists from Rutgers, neighboring academic institutions, and industrial partners.
  3. Organizing the 3rd Annual Interdisciplinary Quantitative Biology Boot Camp, which will be held January 4-15 2016 in Proteomics and offered as an intensive, full-time Two Credit Winter  Session course. The 2014 and 2015 Boot Camps both attracted more than 100 participants from  across the Rutgers (undergraduate, graduate, and, M.D./Ph.D. students, post-doctoral researchers, faculty, and staff).  The focus of the 2016 Boot Camp will be Drug Discovery and  Development (provided in collaboration with partners in industry), taking participants on the  journey from Target Selection -> US FDA Approval.

Business Model

Seed funding for IQB@R is being provided by the Office of the New Brunswick Chancellor, the Public Health Research Institute, the Rutgers Cancer Institute of New Jersey, and Proteomics. Within three years, the Institute is expected to be fully self-funded from indirect cost returns derived from collaborative grant applications submitted by the Research Working Groups.